- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 04.06. | Zhengye Biotechnology receives Nasdaq bid price deficiency notice | 2 | Investing.com | ||
| 04.06. | Zhengye Biotechnology Holding Limited Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency | 72 | GlobeNewswire (Europe) | Jilin, China, June 04, 2026 (GLOBE NEWSWIRE) -- Zhengye Biotechnology Holding Limited (Nasdaq: ZYBT) (the "Company" or "Zhengye"), a veterinary vaccine manufacturer that encompasses research, development... ► Artikel lesen | |
| 04.06. | Zhengye Biotechnology Holding Ltd - 6-K, Report of foreign issuer | 2 | SEC Filings | ||
| 28.04. | Zhengye Biotechnology Holding Limited Announces Fiscal Year 2025 Financial Results | 108 | PR Newswire | JILIN, China, April 28, 2026 /PRNewswire/ -- Zhengye Biotechnology Holding Limited (Nasdaq: ZYBT) (the "Company" or "Zhengye"), a veterinary vaccine manufacturer... ► Artikel lesen | |
| 28.04. | Zhengye Biotechnology Holding Ltd - 20-F, Annual and transition report of foreign private issuers | - | SEC Filings | ||
| ZHENGYE BIOTECHNOLOGY Aktie jetzt für 0€ handeln | |||||
| 06.04. | Zhengye Biotechnology Holding Limited Announces Implementation of Dual-Class Share Structure | 199 | GlobeNewswire (Europe) | Jilin, China, April 06, 2026 (GLOBE NEWSWIRE) -- Zhengye Biotechnology Holding Limited (Nasdaq: ZYBT) (the "Company" or "Zhengye"), a veterinary vaccine manufacturer that encompasses research, development... ► Artikel lesen | |
| 23.02. | Zhengye Biotechnology Holding Ltd - 6-K, Report of foreign issuer | 2 | SEC Filings | ||
| 10.02. | Zhengye Biotechnology Holding Limited Issues 2026 Chairman's Letter to Shareholders | 793 | GlobeNewswire (Europe) | Jilin, China, Feb. 10, 2026 (GLOBE NEWSWIRE) -- Zhengye Biotechnology Holding Limited (Nasdaq: ZYBT) (the "Company" or "Zhengye"), a veterinary vaccine manufacturer that encompasses research, development... ► Artikel lesen | |
| 03.07.25 | Zhengye Biotechnology Holding Limited Announces Fiscal Year 2024 Financial Results | 363 | PR Newswire | JILIN, China, July 3, 2025 /PRNewswire/ -- Zhengye Biotechnology Holding Limited (Nasdaq: ZYBT) (the "Company" or "Zhengye"), a veterinary vaccine manufacturer... ► Artikel lesen |
9 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| TILRAY BRANDS | 4,155 | +0,85 % | Tilray Brands, Inc.: Hi*Ball Energy erobert Großbritannien und wird zum Vorreiter des neuen "Clean Energy"-Trends | Neue Energie tanken mit Hi*Ball Sparkling Energy Water: Der innovative Energydrink kombiniert natürliches Koffein und funktionelle Inhaltsstoffe mit vollem Geschmack - ohne Zucker, ohne Kalorien und... ► Artikel lesen | |
| VIATRIS | 13,348 | +0,08 % | How Is Viatris' Stock Performance Compared to Other Healthcare Stocks? | ||
| SYNBIOTIC | 1,258 | -2,93 % | EQS-Adhoc: SYNBIOTIC SE: Hempro International GmbH beabsichtigt Antrag auf Eröffnung eines vorläufigen Insolvenzverfahrens | EQS-Ad-hoc: SYNBIOTIC SE / Schlagwort(e): Insolvenz/Angespannte wirtschaftliche Situation
Hempro International GmbH beabsichtigt Antrag auf Eröffnung eines vorläufigen Insolvenzverfahrens... ► Artikel lesen | |
| TONIX PHARMACEUTICALS | 10,650 | +1,96 % | Tonix Pharmaceuticals Holding Corp.: Tonix Pharmaceuticals Secures Second Commercial Payer Agreement for TONMYA, Expanding Total Commercial Coverage to ~52 Million U.S. Lives | Agreement with second leading group purchasing organization (GPO), effective June 1, 2026, provides access to approximately 17 million additional U.S. commercial lives (10% of the ~177 million commercial... ► Artikel lesen | |
| ZEALAND PHARMA | 37,770 | +1,18 % | Nurix, BioNxt Solutions, Zealand Pharma - Neue Therapien sorgen für Fantasie | Der Biotech-Sektor erlebt derzeit eine Phase enormer Dynamik. Besonders Therapien gegen Adipositas, Diabetes, Autoimmunerkrankungen und neurologische Leiden zählen zu den größten Wachstumsmärkten im... ► Artikel lesen | |
| SELLAS LIFE SCIENCES | 7,660 | +8,19 % | SELLAS Life Sciences Group, Inc. - 8-K, Current Report | ||
| UNITED THERAPEUTICS | 467,50 | +0,54 % | United Therapeutics Corp Q1 Income Declines | WASHINGTON (dpa-AFX) - United Therapeutics Corp (UTHR) released a profit for first quarter that Dropped, from last yearThe company's bottom line came in at $274.9 million, or $5.82 per share.... ► Artikel lesen | |
| XORTX THERAPEUTICS | 1,755 | -6,12 % | XORTX Therapeutics Inc (4): XORTX $5-million (U.S.) prospectus offering | ||
| TG THERAPEUTICS | 47,700 | +2,36 % | TG Therapeutics, Inc.: TG Therapeutics Announces Positive Topline Phase 1 Data for Subcutaneous BRIUMVI in Patients with Myasthenia Gravis and Initiation of Potential Registration Directed Randomized Phase 2 Trial | 82% of subjects achieved an MCID in their MG-ADL with a mean >4 point improvement in MG-ADL observed in Phase 1 study of Subcutaneous BRIUMVI in patients with MG (n=11) Potential registration-directed... ► Artikel lesen | |
| SOLIGENIX | 0,377 | -5,73 % | Soligenix axes lymphoma program after phase 3 setback, mulls M&A options | ||
| TALPHERA | 0,840 | -11,58 % | Talphera, Inc.: Talphera Announces First Quarter 2026 Financial Results and Provides Corporate Update | NEPHRO CRRT clinical study expected to be completed this year
Cash and investments of $21.1 million at March 31, 2026
Conference call and webcast to be held on Wednesday... ► Artikel lesen | |
| SAVARA | 4,816 | +0,69 % | Savara Inc.: Savara Announces the U.K. Medicines and Healthcare Products Regulatory Agency (MHRA) Has Accepted the MOLBREEVI* Marketing Authorisation Application (MAA) for Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP) | -- MHRA's Acceptance Follows Acceptance/Validation of MOLBREEVI Biologics License Application (BLA) and MAA in Autoimmune PAP by the U.S. Food and Drug Administration (FDA) and the European Medicines... ► Artikel lesen | |
| SCYNEXIS | 3,845 | -5,06 % | XFRA 135: AUSSETZUNG/SUSPENSION | DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTILSCYNEXIS INC. DL... ► Artikel lesen | |
| THERIVA BIOLOGICS | 0,250 | -4,33 % | Theriva Biologics, Inc.: Theriva Biologics Announces Results from VCN-01 Phase 1 Clinical Trial in Head and Neck Cancer Published in Clinical Cancer Research | - Prolonged overall survival (OS) was observed in heavily pre-treated refractory Head & Neck Squamous Cell Carcinoma (HNSCC) patients administered IV VCN-01 prior to the immune checkpoint inhibitor... ► Artikel lesen | |
| WAVE LIFE SCIENCES | 5,400 | +0,93 % | Wave Life Sciences Ltd.: Wave Life Sciences Announces Positive Update on RestorAATion-2 Trial: WVE-006 (GalNAc-RNA Editing) Achieves MZ-Like Phenotype Across Both Biweekly and Monthly Dosing | Data reinforce WVE-006's potential to address both lung and liver manifestations of AATD with a durable, convenient, and safe therapy capable of recapitulating the protective MZ-like phenotype with... ► Artikel lesen |
ZHENGYE BIOTECHNOLOGY HOLDING LIMITED gehört der Branche Pharma an. Die relative Kursveränderung beträgt aktuell 0,00 % bei einem Aktienkurs von 0,804 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ZHENGYE BIOTECHNOLOGY HOLDING LIMITED finden Sie auf Wallstreet Online.